Inactivation of tumour-suppressor genes by homozygous deletion is a prototypic event in the cancer genome, yet such deletions often encompass neighbouring genes. We propose that homozygous deletions in such passenger genes can expose cancer-specific therapeutic vulnerabilities when the collaterally deleted gene is a member of a functionally redundant family of genes carrying out an essential function. The glycolytic gene enolase 1 (ENO1) in the 1p36 locus is deleted in glioblastoma (GBM), which is tolerated by the expression of ENO2. Here we show that short-hairpin-RNA-mediated silencing of ENO2 selectively inhibits growth, survival and the tumorigenic potential of ENO1-deleted GBM cells, and that the enolase inhibitor phosphonoacetohydroxamate is selectively toxic to ENO1-deleted GBM cells relative to ENO1-intact GBM cells or normal astrocytes. The principle of collateral vulnerability should be applicable to other passenger-deleted genes encoding functionally redundant essential activities and provide an effective treatment strategy for cancers containing such genomic events.
Large-scale analysis of the cancer genome has provided an unprecedentedly detailed picture of the genetic anatomy of cancer 1 , which has been, and continues to serve as, a blueprint for the development of molecular-targeted therapies. Targeted therapies directed against amplified or mutant-activated key driver oncoproteins have provided encouraging clinical progress 2 , whereas exploiting loss-of-function mutations or gene deletions has received considerably less attention and has not been as successful thus far. Previous therapeutic work in the area of loss-of-function mutations and deletions has focused specifically on tumour-suppressor genes by strategies that include synthetic lethal approaches. One notable example of a synthetic lethal interaction is the response of BRCA1-mutant cancers to poly(ADPribose) polymerase inhibitors, although this interaction seems to be dependent on genetic context 3, 4 , and can be bypassed in late-stage tumours [3] [4] [5] . Most other synthetic lethal interactors of inactivated tumour suppressors seem to be less robust in eliciting cancer cell death 5 , perhaps because such genes typically do not perform fundamental housekeeping functions.
Cancer genomes are characterized by numerous copy number amplifications and deletions, which target driver oncogenes and tumour-suppressor genes, respectively. Often, these genomic alterations are large regional events, affecting many other genes in addition to the intended target(s). The fact that such broad genomic alterations are not negatively selected against in cancer cells indicates that, on their own, the copy number alterations of these neighbouring passengers must not carry severely detrimental biological consequences. That said, it is conceivable that these passenger genomic events can create unintended (collateral) vulnerabilities unique to those cells; such as when a passenger being co-deleted is a member of a redundant multigene family serving an essential housekeeping function. A large body of genetic interaction studies in invertebrates as well as mice indicates that many essential cellular housekeeping functions are carried out by several homologous genes that encode overlapping functions; this redundancy enables cell viability after loss of one homologue but causes lethality after the loss of several homologues 6-10 ( Supplementary Fig. 1 ). In this conceptual framework, we proposed that the homozygous deletion of redundant essential housekeeping genes could create cancer-specific vulnerabilities ( Supplementary Fig. 1a ), in which pharmacological inactivation of the second, non-deleted homologue would result in the complete loss of activity in tumour cells carrying the deletion, without compromising the health of normal cells, in which both genes are intact and expressed ( Supplementary Fig. 1b ).
ENO1 is a redundant housekeeping gene deleted in GBM
By examining The Cancer Genome Atlas (TCGA) GBM data set for homozygous deletions targeting genes involved in essential cell activities 1 , we identified various such candidates, including the ENO1 gene, which resides at the 1p36 tumour-suppressor locus (see Table 1 for a summary and Supplementary Table 1 for more detailed methodological support). Enolase, which is encoded by three homologous genes, is an essential enzyme that catalyses the second to last step of glycolysis, converting 2-phosphoglyceric acid into phosphoenolpyruvate 11 . In mammals, enolase activity is encoded by three genes: ENO1, which is ubiquitously expressed 12, 13 ; ENO2, which is expressed exclusively in neural tissues 12, 14 ; and ENO3, which is expressed in muscle tissues 15 (Supplementary Table 2 ). ENO1 is the major enolase isoform in GBM, accounting for 75-90% of cellular enolase activity 12 . Given the crucial importance of glycolysis for energy generation and anabolic processes in normal and especially tumour cells 16 , GBM tumours homozygous null for ENO1 would be predicted to be highly sensitive to the inhibition of enolase 2, whereas normal neural tissues should not be affected because of the functional redundancy of enolase 1 (Fig. 1a, b ). Correspondingly, Eno2 knockout mice are viable and fertile, suggesting that pharmacological inhibition of enolase 2 is likely to be well tolerated at the organism level (Supplementary Table 2 ). Moreover, Saccharomyces cerevisiae, which possesses several enolase homologues, shows weak phenotypes with single mutants and incurs cell lethality only when all homologues are deleted [8] [9] [10] ; whereas Caenorhabditis elegans and Drosophila possess only one gene encoding enolase activity, and its deletion is lethal 17, 18 .
The 1p36 locus, which contains several candidate tumoursuppressor genes, including CHD5 and CAMTA1 (refs 19, 20) , sustains frequent deletion in GBM ( Fig. 2a ). The 1p36 locus is homozygously deleted in 1-5% of GBMs 1, 21, 22 (as well as oligodendrogliomas 23 and large-cell neuroendocrine lung tumours 24 ), and ENO1 is often included in the deletion. By examining the TCGA copy number aberrations (single nucleotide polymorphism (SNP) and array comparative genomic hybridization (aCGH) data) 1 and expression profiles, we identified 5 out of 359 GBM samples with homozygous deletion of ENO1 and associated near-complete absence of its expression ( Fig. 2b and Supplementary Fig. 2 ). We identified two GBM cell lines, D423-MG 22 and Gli56 (ref. 25) , with homozygous deletions at the 1p36 locus spanning ENO1. A third GBM cell line, D502-MG 22 , also incurs homozygous deletion of many genes in this locus but not ENO1, thus serving as an excellent control ( Fig. 2c ). Western blot analysis confirmed the loss of ENO1 and the retention of ENO2 protein in D423-MG and Gli56 cells, whereas both proteins were present in D502-MG and in all other glioma and normal glial cell lines tested ( Fig. 2d ).
ENO2 knockdown inhibits growth of ENO1-deleted cells
We used the D502-MG (ENO1 expressing) and D423-MG (ENO1null) cell lines to assess the impact of short hairpin RNA (shRNA)mediated knockdown of ENO2 in an ENO1 wild-type or null context. Two independent ENO2 shRNAs (pLKO.1 vector) resulted in robust protein reduction and led to a profound inhibition of cell growth only in the context of ENO1 genomic deletion ( Supplementary Fig. 3 ). We obtained the same result using a further, independent ENO2 shRNA (pGIPZ vector) ( Supplementary Fig. 4a, b ). Furthermore, shRNA ablation of ENO2 in ENO1-null cells also resulted in decreased soft agar colony formation and blocked the in vivo tumorigenic potential of intracranially injected cells ( Fig. 2e and Supplementary Fig. 4c ). Finally, the selective toxicity of ENO2 ablation to ENO1-null cells was demonstrated in an isogenic context using the doxycycline-inducible TRIPZ vector. When we used this doxycycline-inducible system in ENO1 wild-type cell lines (U87, A1207 and LN319), two independent shRNAs reduced ENO2 protein levels by .70% (Fig. 3a ) with no impact on ENO1 levels (data not shown). This ENO2 ablation resulted in a profound inhibition of cell proliferation only in the ENO1-null D423-MG cell line ( Fig. 3b ). Furthermore, enforced expression of hairpin-resistant ENO2 open reading frame fully reversed the deleterious effects of the ENO2 shRNA ( Supplementary Fig. 5 ), showing that the inhibitory effect of the hairpin was indeed specific to diminished ENO2 expression and was not an off-target effect. Finally, when ENO1 was ectopically re-expressed in D423-MG (ENO1-null) cell lines at levels similar to those observed in ENO1 wild-type GBM lines, the deleterious effect of shRNA ablation of ENO2 was completely abrogated ( Supplementary Fig. 6 ).
Enolase inhibition is toxic to ENO1-null cells
Next, we assessed the effect of pharmacological inhibition of enolase activity in ENO1 wild-type and null cells. Previous studies have focused on the pharmacological inhibition of enolase, in particular for antiparasitic purposes 26, 27 , and many compounds have been characterized, most of which act as reaction-intermediate analogues ( Supplementary Table 3 ). The most potent enolase inhibitor is phosphonoacetohydroxamate (PHAH) 27 , which is thought to act as a transition-state analogue with an inhibitory constant of 15 pM on yeast enolase. Although PHAH has not been tested on human enolases, previous work demonstrated inhibitory effects on enolases from distantly related organisms 27, 28 , suggesting its potential use over a large phylogenetic distance. We find that PHAH was indeed capable of potent inhibition of enolase in vitro in native lysates of human GBM cell lines, with a half-maximum inhibitory concentration (IC 50 ) of around 20 nM ( Fig. 4b and data not shown). We used PHAH in concentrations ranging from 0.625 mM to 50 mM and 
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observed marked toxicity in ENO1-null cells (Fig. 4a, c and Supplementary Fig. 7 ) and minimal impact on the ENO1 wild-type controls, which show at least ten times greater enolase activity relative to the ENO1-null cells (because ENO1 accounts for 90% of the total cellular enolase activity 12 ; Fig. 4b ). Although the IC 50 of PHAH is similar for ENO1 and ENO2 in vitro (data not shown) the greater toxicity of the inhibitor to ENO1-null cells (Gli56 and D423-MG) derives from the fact that in these cells enolase activity is already 90% lower than in wild-type ENO1 cell lines, and consequently, a much lower dose is required to decrease total enolase activity below the toxicity threshold. Further data indicate a direct relationship between the levels of enolase activity and the sensitivity to PHAH across different cell lines and in the same cell line with different levels of enforced enolase expression. First, U343 and D502-MG cells, which have intermediate levels of enolase activity (and ENO1 protein expression; Fig. 2d ) compared with the other cell lines, have intermediate levels of sensitivity to PHAH (Fig. 4) , which in the case of U343 can be rescued by ectopic overexpression of ENO1 or ENO2 (data not shown). A systematic titration of PHAH in D423-MG cell lines with varying levels of enforced ENO1 or ENO2 expression, shows a direct relationship between the level of enolase expression/ activity and the ensuing resistance to PHAH ( Supplementary Fig. 7) . PHAH toxicity was also abrogated in Gli56 ENO1-null cells by ectopic expression of physiological levels of ENO1 or overexpression of ENO2 ( Supplementary Fig. 7 ). Regarding the mechanism of toxicity, cell cycle and apoptosis analysis demonstrated that PHAH treatment for 48 h induced a marked decrease of S-phase cells followed by a marked increase of apoptosis in D423-MG but not in ENO1 wild-type U373 cells ( Supplementary Table 4 ). This effect was completely rescued by ENO2 overexpression (data not shown). The fact that this growth inhibition and subsequent apoptosis is due to energy crisis is substantiated by a strong induction of phosphorylated 59-AMPactivated protein kinase (AMPK) (at Thr 172) 29 , which was observed in D423-MG but not in ENO1 wild-type cell lines (data not shown). It is tempting to speculate that this energy stress response exerts a protective effect, and thus the concomitant addition of an AMPK inhibitor together with PHAH could result in further toxicity. Finally, it is worth noting that ENO1-null cells do not show any greater sensitivity to other molecular-targeted therapies, such as a combination of receptor tyrosine kinase inhibitors 30 (lapatinib, sorafenib and PHA665752) ( Supplementary Fig. 8 ) and rapamycin (data not shown) compared with wild-type ENO1 cells. These data indicate that D423-MG cells are not broadly susceptible to other anticancer agents and that PHAH selectively targets ENO1-null GBM cells.
Discussion
In this study, we sought to determine the effect of collateral deletion of genes in tumour-suppressor loci that belong to redundant gene families playing cell-essential roles, and to assess whether extinction of remaining gene family members would create cancer-specific vulnerabilities. We provide genetic and pharmacological evidence that enolase 2 inhibition is lethal in cells with 1p36 homozygous deletion with collateral loss of ENO1, whereas ENO1-intact cells can rely on Figure 3 | shRNA ablation of ENO2 affects ENO1-null but not ENO1-WT GBM cells. a, shRNA ablation by two independent doxycycline (Dox)-inducible TRIPZ hairpins against ENO2 (shENO2-3, shENO2-4) resulted in .70% reduction in enolase 2 protein levels in both ENO1 wild-type (WT) (A1207, U87 and LN319) and ENO1-null (D423-MG) cell lines. b, Ablation of ENO2 markedly inhibited growth of ENO1-null but not wild-type ENO1 cells, whereas nontargeting shRNA against luciferase (shLuc) had no effect in any cell line (n 5 3 biological replicates, mean 6 s.e.m., Student's t-test). Representative plates at the last time point of growth for cells infected with shLuc, shENO2-3 or shENO2-4, with or without Dox induction, are shown to the right of growth curves for each cell line. RESEARCH ARTICLE enolase 1 to undergo glycolysis and support survival. These findings are in agreement with genetic data from invertebrates [8] [9] [10] . Given that several homozygously deleted housekeeping genes can occur in the same deletion on 1p36 (for example, H6PD; Supplementary Table 1) , it may be possible to increase the effectiveness and cancer cell-specific killing further by combining the inhibition of ENO2 with that of another homologue of a simultaneously deleted housekeeping gene.
Attempts to therapeutically exploit general metabolic differences between normal and cancer cells, such as glucose addiction (the Warburg effect) and glutamine or serine addiction 16, 31, 32 , remain areas of active preclinical investigation and clinical development. The approach described here is distinguished from these attempts in that it does not rely on any general aspect of cancer cell metabolism, but rather rests on genetically determined metabolic differences between normal and cancerous tissue to generate cancer cell-specific vulnerabilities. We propose that collateral vulnerability may be extended to other passenger homozygously deleted housekeeping genes in loci sustaining frequent deletion, such as 9p21 (CDKN2A) and 10q23 (PTEN), which contain members of functionally redundant housekeeping gene families ( Table 1 , Supplementary Table 1 and Supplementary Fig. 9 ). The strongest pharmacologically targetable candidates in this list are the homologues of the dual-function energy metabolism/iron regulator aconitase 1 (ACO1; 9p21) and the coenzyme A biosynthetic enzyme, pantothenate kinase 1 (PANK1; 10q23). Importantly, many of the compounds targeting the homologues of these passenger genes represent new molecular entities with respect to cancer treatment.
By one estimate, 11% of all protein-coding genes in the human genome are deleted in human cancers 33 . Thus, given the large number of homozygous deletions across many different cancer types spanning many hundreds of genes [33] [34] [35] [36] , the model described here for GBM should be applicable to the development of personalized treatments for many other cancer types.
METHODS SUMMARY
Cells were cultured using standard techniques in DMEM with 20% fetal bovine serum. shRNA experiments were conducted by lentiviral production through transient transfection of 293T cells followed by transduction in medium containing 4 mg ml 21 polybrene and selection with 2 mg ml 21 puromycin. shRNA expression was induced with 1 mg ml 21 doxycycline and knockdown was tested by western blot. The shRNA-resistant ENO2 open reading frame was created by introducing silent mutations with the QuickChange site directed mutagenesis kit from Stratagene and then cloning into the pHAGE-CMV lentiviral vector. Cell proliferation experiments were performed using crystal violet staining, the CellTiter-Glo assay (Roche) and by measuring confluence using IncuCyte (Essen Bioscience). Orthotopic intracranial injections of D423-MG cells with and without ENO2 knockdown in severe combined immunodeficient (SCID) mice were performed as previously described 37 . Soft agar colony formation assay of these cells was performed using standard techniques by seeding 10 4 cells in 6-well plates. For the inhibitor studies, PHAH lithium salt was customsynthesized by TCRS, following a previous protocol 28 . For the enolase activity assay, NADH oxidation was measured in a pyruvate kinase-lactate dehydrogenase coupled reaction as previously described 12 . For cell cycle studies, cells were incubated with or without PHAH for 48 h, stained with propidium iodide and sorted by flow cytometric analysis. For annexin V/7-AAD assays, cells were treated with or without PHAH for 96 h, stained with annexin V-phycoerythrin (PE) and 7-AAD, and evaluated for apoptosis by flow cytometry according to the manufacture's protocol (Biovision). Fig. 3a , in which for the cell line U87, an additional non-targeting short hairpin RNA control (original lanes 7 and 8) was excised with the remaining halves of the blot and merged, which is now indicated by a dashed line. We also note that in the published Fig. 3a , lanes 1 and 2 of the original U87 vinculin blot were accidentally used as the loading control for shENO2-4 (lanes 9 and 10 of the original unprocessed ENO2 blot in the Supplementary Information), and lanes 9 and 10 of the vinculin blot should have been used as the correct loading control lanes. The correct loading control lanes are now shown (Supplementary Information). None of these corrections alter the original meaning of the experiments, their results, their interpretation, nor the conclusions of the paper. We apologize for any confusion this may have caused to the readers of Nature.
Supplementary Information is available in the online version of this corrigendum. 
